Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified-release tacrolimus versus standard tacrolimus after kidney transplantation
2004-000304-41Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Aug 2004
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tacrolimus in chronic kidney disease (CKD) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Biopsy-proven acute rejection within 24 weeks. Started Aug 2004; status: completed.
02
Drugs
tacrolimus
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2004-000304-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000304-41.